Papers, explained in our own words

1. Lipid Nanoparticles as Carriers for RNAi against Viral Infections Current Status and Future Perspectives

Torrecilla J, Rodríguez-Gascón A, Solinís Má, Del Pozo-Rodríguez A

Naked RNAi molecules are rapidly degraded by serum nucleases and cannot readily cross cell membranes because of their negative charge. Effective delivery systems are therefore required to exploit RNAi for antiviral therapy. Lipid nanoparticles (LNPs) are attractive because they are relatively safe, simple to produce, protect encapsulated RNA, and can be functionalized for targeting or combined with conventional drugs. Up to January 2014, infectious diseases ranked third among gene therapy clinical trial indications, with 164 trials (8.2%). - HCV: apo A-I cationic liposomes with HCV-core siRNA inhibited viral expression by 65–75% in.